The AHA/ACC joint committee developed 5 performance measures and 16 quality measures to improve adherence to evidence-based recommendations and advance the quality and equity of atrial fibrillation care.
The AHA/ACC developed 21 performance and quality measures to improve adherence to evidence-based recommendations and advance equitable care for patients with atrial fibrillation.
Atrial fibrillation (AF) is increasing in incidence, prevalence, and lifetime risk, and contributes to substantially greater health care costs and increased risks of stroke, heart failure, and mortality. Improving adherence to evidence-based recommendations equitably in AF is critical to advancing clinical care, patient outcomes, and public health. The writing committee developed a comprehensive set of 5 performance measures, which are appropriate for public reporting or pay-for-performance programs, and 16 quality measures, which are useful to clinicians and health care organizations for quality improvement. The writing committee selected the measures from the strongest recommendations (Class 1 or 3) in the “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.” The purpose of the writing committee’s performance measures is meant to ensure that patients with newly diagnosed AF receive a basic clinical evaluation, with an emphasis on secondary prevention for patients at all stages of AF, documenting stroke risk, and, if indicated, providing appropriate anticoagulation. AF quality measures cover a variety of topics including measuring and addressing health inequities, optimizing antiarrhythmic or anticoagulant treatment, engaging in shared decision-making for rate- versus rhythm-control strategies, and, in appropriate patients, offering catheter ablation for those with heart failure with reduced ejection fraction. The performance and quality measures are intended to advance the quality and equity of AF care across all patient populations with AF.
“The 16 quality measures cover a variety of topics including measuring and addressing health inequities, optimizing antiarrhythmic or anticoagulant treatment, engaging in shared decision-making for rate vs. rhythm-control strategies, and, in appropriate patients, offering catheter ablation for those with heart failure with reduced ejection fraction.”
Benjamin et al. (Mon,) conducted a review in Atrial fibrillation. Clinical Performance and Quality Measures was evaluated. The AHA/ACC joint committee developed 5 performance measures and 16 quality measures to improve adherence to evidence-based recommendations and advance the quality and equity of atrial fibrillation care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: